tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Summit Therapeutics reports Q2 EPS (5c), consensus (6c)

Aggregate cash and cash equivalents, restricted cash, and short-term investments were $325.8M and $186.2M at June 30 and December 31, 2023, respectively.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1